Clinical trial
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)
ClinicalTrials.gov ID: NCT01865747
Sponsor: Exelixis
Information provided by: Exelixis (Responsible Party)
Last Update Posted: 2021-04-27
Brief Summary:
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Official Title:
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Intervention / Treatment:
- Drug: Cabozantinib tablets
- Drug: Everolimus (Afinitor) tablets
| Category | Value |
|---|---|
| Study Start (Actual) | 2013-06 |
| Primary Completion (Actual) | 2015-05-22 |
| Study Completion (Actual) | 2021-01-15 |
| Enrollment (Actual) | 658 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
XL184-308
|